Recent preclinical studies utilizing in vitro glioblastoma stem cells (GCS) models and GB orthotopic xenograft model with EGFR variant III showed antitumor activity along with inhibition of EGFR downstream signaling pathway for the third-generation EGFR inhibitor osimertinib (26). Here, EGFR is linked to glioblastoma.